Embolotherapy – A Powerful Minimally Invasive Alternative to Surgery in Many Clinical Situations

The Global Embolotherapy Market pegged at US$ 3.2 billion (2020) is expected to witness a growth rate of ~7.7% from 2021 to 2031.

Rising incidence of peripheral vascular diseases, uterine fibroids, liver cancers, strokes, growing patient preference for minimally invasive procedures, rising investments for R&D activities, technological advancements, expanding applications of embolotherapy for different clinical indications, and favorable coverage policies are some of the pivotal factors propelling the growth of the embolotherapy market. However, procedural complications and product recalls are likely to hinder the growth of the market to a certain extent.

Clairvoyance Research conducted an in-depth market analysis study of the Global Embolotherapy Market. The study comprehensively analyzes the market from different perspectives and provides granular insights on hot revenue pockets, headwinds & tailwinds impacting the market, quantitative (market size & forecasts) & qualitative analysis on different segments, key strategies, and competitive landscape.

Access ‘Sample Pages’ of the Report

Intriguing Benefits of Embolotherapy and its Growing Application Horizon Set to Drive the Global Embolotherapy Market

Embolotherapy is a minimally invasive procedure that stops blood flow in target areas. It is a type of endovascular treatment that aims to occlude abnormal blood vessels to control or prevent hemorrhaging. Embolotherapy has emerged as an alternative to invasive surgery in urgent cases of massive bleeding. The applications of embolotherapy have expanded significantly and are widely adopted by interventional radiologists around the world for numerous clinical situations. The most cutting-edge applications are gastric artery embolization for weight loss and prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH). PAE is considered a viable choice for the treatment of lower urinary tract symptoms (LUTS) caused by obstruction secondary to BPH, and more than 800 cases are performed worldwide. The therapy also finds its application in the musculoskeletal system to treat resistant painful conditions such as osteoarthritis, frozen shoulder, and overuse injuries. It is also used in women for the treatment of uterine fibroids and has reported around 85% success rate worldwide. Moreover, it is also used in the treatment of certain cancers, especially liver cancer.

New Product Launches Set to Catapult the Market

Prominent players are continuously focusing on maintaining their leadership position in the market by continuously introducing new products and improving the existing products to broaden the use of embolotherapy techniques. For instance, in July 2021, Terumo Medical Corporation announced the launch of its AZUR™ Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.

Procedural Complications and Recall of Defective Products - An Area of Concern

Rapid developments in interventional radiological technology and embolism material have expanded the clinical indications of embolotherapy. However, complications related to materials and procedures are expected to hamper the growth of the market. The complications related to material include poor flowability of the solid embolic agent that makes it difficult to uniformly embolize the peripheral vessel and obstructive nephropathy caused by the solid embolic agent. Whereas, risk of infection, allergic reaction, and damage to the blood vessels from the catheter are the risk areas related to the procedure.

Frequent product recalls and related losses are expected to further restraint the growth of the market. Defective products can cause serious harm to patients and can also lead to significant financial & reputational damage to the company. Product recalls can have a significant & long-term effect on a brand and can undermine the trust of customers in a specific brand. For instance, in Sept 2021, Medtronic recalled its pipeline flex embolization devices for the risk of delivery system fractures during the device's placement, retrieval, or movement. The FDA has identified this as a Class I recall, the most serious type of recall. The use of these devices may cause serious injuries or death. There have been around 59 reported device malfunctions cases, 10 serious injuries, and two deaths related to this recall.

Snapshot - Competitive Landscape

The embolotherapy market is marked by the presence of prominent players such as Terumo Medical Corporation, Boston Scientific Corporation, Medtronic, Abbott, Penumbra, Inc., Merit Medical Systems, Cook, Johnson & Johnson Services, Inc., Stryker, and Acandis GmbH. Other players operating in the market are KANEKA CORPORATION, Meril Life Sciences Pvt. Ltd., Balt, SIR-Spheres, among others.

For deep-rooted insights, please follow the link

NEED MORE?

• Talk to us about your requirements and get a customized report
• Get more details about the content of the report
• Request a Free ‘Sample Pages’ of the report